Patents vs. Market Exclusivity: Why Does it Take so Long to Bring Generics to Market?
By Zachary Brennan -
Published 17 August 2016
It’s well known that generic drugs are just as safe and effective as their brand name counterparts. They’re the cheap knockoffs that help more people around the world gain access to innovative and sometimes life-saving treatments; the boring copycats made by companies you’ve never heard of and sold in plain bottles with little fanfare.
Categories: News, US, FDA, Business Skills, Drugs, Government affairs, Quality, Regulatory intelligence, Regulatory strategy
Tags: pharmaceutical patents, pharmaceutical IP, generic drugs, ANDA approval process